Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six distinct surveys with input from more than 3,000 individuals at varying stages of their cancer experience.
Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).
Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
To see Dr. Paz-Ares discuss this video in Spanish, please click here.
Eric Roeland, MD, of the University of California, San Diego, and Jennifer S. Temel, MD, of Massachusetts General Hospital, discuss findings that showed the benefits of offering palliative care integrated with oncology care (Abstracts 10003 and 10131).
